Clinical trials registry: ClinicalTrials.gov URL: http://clinicaltrials.gov. Unique identifier: NCT00110461.
Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study
Article first published online: 25 FEB 2013
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
Volume 15, Issue 2, pages 138–149, March 2013
How to Cite
Findling, R. L., Correll, C. U., Nyilas, M., Forbes, R. A., McQuade, R. D., Jin, N., Ivanova, S., Mankoski, R., Carson, W. H. and Carlson, G. A. (2013), Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disorders, 15: 138–149. doi: 10.1111/bdi.12042
- Issue published online: 25 FEB 2013
- Article first published online: 25 FEB 2013
- Received 10 January 2012, revised and accepted for publication 13 October 2012
- bipolar disorder;
Objective: To evaluate the long-term efficacy, safety, and tolerability of aripiprazole in pediatric subjects with bipolar I disorder.
Methods: A randomized, double-blind, 30-week, placebo-controlled study of aripiprazole (10 or 30 mg/day) in youths (10–17 years) with bipolar I disorder (manic or mixed) ± psychotic features (n = 296) was performed. After four weeks, acute treatment completers continued receiving ≤26 weeks of double-blind treatment (n = 210). The primary outcome was Young Mania Rating Scale (YMRS) total score change.
Results: Of the 210 subjects who entered the 26-week extension phase, 32.4% completed the study (45.3% for aripiprazole 10 mg/day, 31.0% for aripiprazole 30 mg/day, and 18.8% for placebo). Both aripiprazole doses demonstrated significantly (p < 0.001) greater improvements in YMRS total score at endpoint compared with placebo in protocol-specified last observation carried forward analyses, but not in observed case or mixed-model repeated measures at week 30. Overall time to all-cause discontinuation was longer for aripiprazole 10 mg/day (15.6 weeks) and aripiprazole 30 mg/day (9.5 weeks) compared with placebo (5.3 weeks; both p < 0.05 versus placebo). Both aripiprazole doses were significantly superior to placebo regarding response rates, Children’s Global Assessment of Functioning and Clinical Global Impressions-Bipolar severity of overall and mania scores at endpoint in all analyses. Commonly reported adverse events included headache, somnolence, and extrapyramidal disorder.
Conclusions: Aripiprazole 10 mg/day and 30 mg/day were superior to placebo and generally well tolerated in pediatric subjects with bipolar I disorder up to 30 weeks. Despite the benefits of treatment, completion rates were low in all treatment arms.